Transgender Health and HIV
Transgender persons illuminate the complex interplay of social and biological factors that determine gender identity (an individual's own sense of maleness or femaleness) and contribute to both HIV risk and HIV health. This article highlights some of the unique challenges that transgender persons face in maintaining their health -- including avoiding HIV infection or living well with HIV -- and discusses ways in which health-care providers can better equip themselves to provide care that meets the needs of transgender clients.
Sex and gender are closely related concepts that encompass complex biological, behavioral, social, and cultural attributes. While "sex" is commonly used to classify persons as male or female based on their genetic make-up and reproductive organs, "gender" refers to an individual's self-representation and includes the array of social beliefs, norms, customs, and practices that define "masculine" and "feminine" attributes and behavior. "Gender identity" refers to persons' perceptions of their own gender, including their personal identity as male, female, or some variation.
"Transgender" is an inclusive term for persons whose genitals, gender identity, and/or gender expression differ from the sex assigned to them at birth. They may strongly identify with one gender or with something outside the "male/female" view of gender that is prevalent in Western cultures. Various gender identities fall under the "transgender" umbrella, including (but not limited to) transgender woman, transgender man, male-tofemale (MTF), female-to-male (FTM), transsexual, drag queen/king, gender variant, and genderqueer. While some transgender persons seek physical transformation through the use of hormones, sex reassignment surgery, or cosmetic procedures, others pursue masculine or feminine gender expression through behavior or self-presentation (for example, by dressing as a man or a woman).
Transgender people may identify as heterosexual, homosexual, or bisexual (or as none of the above). According to gender scholars Suzanne Kessler of the State University of New York and Wendy McKenna of Barnard College, "Transgenders make clear that while sex, gender, and sexual orientation are interrelated, they are also separate. Thus sex, which is given at birth, does not determine gender or sexual orientation; neither does gender determine sexual orientation or vice versa."
Because of the small reported numbers of transgender persons in the United States and elsewhere, little effort has been made to create a new demographic category for the purpose of epidemiology (that is, for tracking health conditions, including HIV, in different populations). MTF transgender persons have often been categorized as "men who have sex with men" (MSM) in epidemiological data collection -- a label that may not accurately reflect their gender identity or sexual orientation. For example, one study found that the majority of MTF in the study sample identified as heterosexual and had biologically male sex partners.
The general lack of inclusion of gender-variance variables in health surveys makes collecting true estimates of the transgender population and the transgender HIV positive population that much more difficult. While the terms MTF and FTM are commonly used, it is important to note that these are medicalized terms and do not necessarily represent the identities of all individuals who fall under the "transgender" umbrella. The Center of Excellence for Transgender HIV Prevention, part of the University of California at San Francisco (UCSF), suggests a two-question system that distinguishes "sex" from "gender" for data collection purposes (see sidebar).
Since no true population-based studies have been conducted and U.S. and global health surveys rarely include gender-variance variables, the data remain extremely patchy. Estimates published by the American Psychiatric Association in 2000 suggest that, in "smaller countries in Europe," 1 in every 30,000 persons is MTF and 1 in every 100,000 is FTM. By contrast, Greit De Cuypere of Belgium's Ghent University Hospital and colleagues estimate that 1 in 12,900 persons is MTF and 1 in 33,800 persons is FTM in Belgium. In addition to being derived from geographically limited samples, these figures are based on the number of transgender persons seeking mental health care or medical treatment, and may therefore dramatically underestimate the true number of individuals who identify as transgender. Despite the tremendous gaps in our knowledge about the extent of the transgender population, however, it is necessary to look at what data do exist for a better understanding of the effect of HIV on the transgender community.
A recent meta-analysis by Jeffrey Herbst of the U.S. Centers for Disease Control and Prevention and colleagues estimated a U.S. HIV prevalence of 27.7% among MTF, based on four studies in which HIV status was confirmed by testing, whereas a mean prevalence of 11.8% was found among MTF across 17 studies relying on selfreported HIV status. Rates of HIV infection are believed to be much lower among FTM persons; for example, a 2% HIV prevalence among FTM was found in a San Francisco-based study in which HIV status was confirmed by testing, and up to 3% prevalence has been reported in nationwide studies in which HIV status was self-reported. However, lack of knowledge of transmission and prevention means, the misperception that FTM are at intrinsically low risk for HIV, and inconsistent use of latex barrier methods during vaginal and anal sex may all increase risk for FTM individuals.
Research on transgender health has tended to focus on MTF, and such studies have generated a wide range of HIV prevalence estimates, ranging from 11% to 78%. Assessments from across the United States have found varying HIV prevalence rates among MTF persons, from 14% in Chicago to 25% prevalence among a sample of people of color in Washington, DC, to 27% in Houston. The San Francisco Department of Public Health has been collecting health-related data on transgender persons from medical records since 1996; however, as with national and state-wide data, these data vary by study, depending largely on whether data are gathered through testing or self-report. Thus, estimated HIV-infection rates for MTF in San Francisco range from 35% to 48%.
The state of California and the city and county of San Francisco are notable in their attempts to collect epidemiological data for the transgender population. In 2002, "FTM" and "MTF" became gender reporting options in publicly funded HIV counselling and testing sites in California. Transgender persons have the overall highest HIV diagnosis rate (6.3%) of any group in the state, higher than that of MSM (4.8%). Over half of these cases are in the San Francisco Bay Area; one-third are in Los Angeles and Southern California. African Americans bear the greatest HIV burden among the state's transgender persons, with the highest rate of HIV diagnosis (28.6%).
Transgender persons face myriad challenges that place them at increased risk for HIV infection. Precarious economic status, substance use, low self-esteem, social vulnerability, and lack of social support are common barriers to adopting and maintaining safer behaviors that can prevent the acquisition or transmission of HIV.
Economic Marginalization and Sex Work
Economic marginalization as a result of institutional discrimination, stigma, and lower levels of education contributes to a severe lack of opportunity for many transgender persons. Studies have found that over one-third of MTF have experienced job discrimination, over one-fifth report income below the U.S. poverty level, and nearly two-thirds of 16-to-25-year-olds are unemployed. Such marginalization may lead MTF to engage in commercial sex work as a means of economic support. Forty-two percent of MTF in a recent meta-analysis reported participation in commercial sex work, as did 59% of transgender youth in another study.
Many MTF find that sex work offers a sense of social connection with other transgender persons, but sex work amplifies the risk of HIV transmission for MTF and their partners. Not only is HIV prevalence high among MTF engaged in sex work, it also appears that their infection rates are as much as four times higher than those of genetically female sex workers.
Sexual Practices and Partnerships
HIV risk among MTF is not limited to exposure through sex work, however; sexual practices and partnership arrangements also play a role. The desire to affirm a feminine gender identity may lead MTF to have concurrent (multiple) sex partners and unprotected receptive anal intercourse (URAI) in high-risk sexual networks with higher HIV prevalence. Concurrent sex partners and URAI appear to be common among MTF: Over one-third of MTF participants in one study reported multiple sex partners and nearly half reported URAI during casual sex.
In a study of MTF of color in San Francisco, URAI with primary and casual sex partners was associated with drug use before sex. Many MTF turn to substances to cope with discrimination, transphobia, and the sex-work environment. A risk-behavior study in San Francisco found that the majority of its transgender sample had a history of using non-injected drugs, including marijuana (90%), cocaine (66%), and speed (57%). In addition, 34% had a history of injecting drugs, and nearly half of these individuals had shared syringes. These substance-use behaviors are established risk factors for HIV infection.
As in other populations, substance use among MTF persons is linked to mental health issues. A recent metaanalysis found that 35% of MTF had experienced anxiety, and 44% reported depression; both anxiety and depression are associated with increased HIV risk. Transgender persons are also nearly twice as likely as non-transgender men or women to have considered or attempted suicide.
MTF may feel socially marginalized due to an absence of social support, rejection by their peers and families, and a lack of connection to the lesbian, gay, and bisexual community, intensifying the risk of HIV transmission and disease progression. Transgender persons report the lowest levels of family support compared with MSM and women who have sex with both men and women. Rejection from family and peers may lead to alienation and feelings of hopelessness, and may increase psychological and social vulnerability -- which may, in turn, increase HIV risk. For example, condoms may be perceived as undermining intimacy with primary partners, while sex with casual partners and willingness to engage in URAI may provide gender validation and a sense of attractiveness that MTF may not get from peers, family, and the larger society. HIV risk thus stems (in part) from willingness to engage with sexual partners who provide a sense of love and acceptance but who may also request unprotected sex.
Body Modification and HIV Risk
Body modification, such as hormone therapy, may offer the benefits of affirming gender identity and both improving self-esteem and reducing discrimination by potential employers and others. However, unless monitored by a competent and knowledgeable health care provider, it may also create significant risk for HIV and other illnesses.
Hormones procured outside of a medical setting (on the street, for example) are typically injected rather than taken orally, and needle sharing may lead to increased risk for acquiring or transmitting HIV and or other bloodborne diseases.
Unsanitary silicone injecting is also common despite the risk of transmitting or acquiring HIV, hepatitis B and C, and multidrug-resistant Staphylococcus aureus (MRSA), as well as the danger of foreign substance reactions, in which the body rejects the silicone (see sidebar below). Nonetheless, many transgender persons who share syringes to inject hormones or silicone do not identify themselves as "drug users" and may not see the potential risk of what is, in fact, needle sharing.
Patients request hormones -- synthetic versions of chemicals that naturally occur in the body and promote sexlinked characteristics, like breast growth -- to develop physical features that allow them to express their gender identity. Hormones are available as pills and injections and in transdermal preparations (delivered through the skin as creams, gels, or patches). FTM persons may choose to take testosterone to increase body hair, deepen the voice, and develop more muscle mass, while MTF individuals may opt to take estrogen to enlarge the breasts, lose body and facial hair, transfer fat from the gut to the hips, and soften the skin. Hormone therapy can have the added benefit of connecting transgender people with medical care, including treatment for HIV and other chronic illnesses and education about HIV prevention.
The table summarizes the types of hormones and hormone-altering drugs and procedures used for feminization and masculinization, along with the permanent and temporary effects, risks, contraindications, and benefits and disadvantages of each.
Standards of Care
The World Professional Association for Transgender Health (WPATH, formerly known as the Harry Benjamin International Gender Dysphoria Association) has established internationally recognized standards of care (SOC) for the treatment of gender identity disorder (GID), defined as distress and social impairment caused by gender identity that is not aligned with birth sex.
The SOC is a consensus on psychiatric, psychological, medical, and surgical management of GID and protocols for hormonal reassignment of gender. Many physicians and transgender persons oppose the GID diagnosis, not viewing transgenderism as a "disorder" but rather as a natural, healthy expression of the range of gender variations that are part of the human experience.
Nonetheless, the SOC guidelines are commonly used for assessing mental health in transgender adults and children, and for managing surgery and hormone treatment in this toooften neglected population. According to the SOC, in order to begin hormone therapy, individuals should:
In some instances, the SOC notes, it may be acceptable to provide hormones to patients who have not fulfilled the third criteria -- for example, to facilitate the provision of monitored therapy using hormones of known quality, as an alternative to black-market or unsupervised hormone use.
To view the latest edition of the World Professional Association for Transgender Health Standards of Care for Gender Identity Disorders, visit http://wpath.org/Documents2/socv6.pdf.
Beginning and Monitoring Hormone Therapy
Hormone therapy for transgender persons is highly individualized and should include medical monitoring. A number of contraindications must be discussed with a knowledgeable heath care provider before hormone use begins, including a history of breast cancer or thrombosis (blood clots) and active substance abuse, as well as use of antiretroviral drugs to manage HIV disease.
Health recommendations for those who wish to begin hormone treatment include smoking cessation, regular exercise, and reducing risk factors for cardiovascular disease. Transdermal or intramuscular hormones may be recommended for older individuals or those with other (non-age-related) risk factors for blood clots.
A large Dutch cohort showed that prescribed and monitored hormone therapy did not increase mortality; rather, the number-one cause of death in this cohort was suicide. As discussed previously, many transgender persons have attempted or committed suicide and often struggle with mental illness. Thirty-two percent of a San Francisco-based sample of transgender persons had attempted suicide; younger age, depression, substance abuse, and a history of forced sex, genderbased discrimination, or gender-based victimization were associated with attempted suicide. Thus, in addition to a full medical history, a complete psychosocial history should be taken and any necessary mental health treatment should be initiated before beginning hormone therapy, to ensure the best possible outcome.
When obtained on the black market, hormones come with no quality assurance, recommended dosages, or medical monitoring. Some transgender persons obtain hormones illegally to supplement prescribed hormones and speed up or intensify the desired effects, which puts these individuals at increased risk for unwanted side effects and drug interactions. Medical monitoring is essential to safe and healthy hormone use.
Hormones and ART
-- JoAnne Keatley, MSW, Director of the Center of Excellence for Transgender HIV Prevention, UCSF
Treatment with hormones may provide an opportunity for patients to address HIV disease. Tom Waddell Health Center (TWHC), a San Francisco-based center that offers a transgender health clinic, advises that transgender health care providers should have expertise in HIV care.
Cross-gender hormone therapy is not contraindicated in HIV-positive people on antiretroviral therapy (ART) at any stage of HIV-disease progression, although health care providers may still be wary, as there is so little medical literature on interactions between hormone therapy and antiretroviral drugs or the impact of hormones on CD4 counts for transgender persons. There is some evidence that certain HIV medications do impact hormone levels; for example, TWHC advises extreme care with the protease inhibitor indinavir (Crixivan) and the non-nucleoside reverse transcriptase inhibitor efavirenz (Sustiva), as they may increase levels of ethinyl estradiol, a form of the hormone estrogen. TWHC also advises transgender patients on hormone therapy to avoid the protease inhibitors fosamprenavir (Lexiva) and amprenavir (Agenerase; no longer widely available in the U.S.) because hormone therapy may decrease blood levels of these drugs by 20%, putting the patient at risk for drug-resistant HIV.
It is important to note that the quantities of hormones required for feminization and masculinization have not been thoroughly tested for interactions with other drugs. Drug interactions involving ethinyl estradiol -- a form of estrogen used in birth control pills -- offer some hints, but much higher doses of ethinyl estradiol are prescribed for hormone therapy for transgender persons compared with those taken for birth control. Decreased or increased levels of ethinyl estradiol in the body may lead to unwanted side effects, ranging from inadequate feminization of physical features to nausea and vomiting, headache, and drowsiness.
Sex reassignment surgery (SRS) -- also called "gender confirmation surgery" -- includes a number of surgical options (see sidebar) which transgender persons may or may not choose to have, depending on their gender identity. SRS can be performed for HIV-positive transgender persons with a CD4 count of 200 cells/mm3 or above. The WPATH Standards of Care state that "it is unethical to deny availability or eligibility for sex reassignment surgeries or hormone therapy solely on the basis of blood seropositivity for blood-borne infections such as HIV, or hepatitis B or C, etc."
As with any surgery, the quality of the care the patient receives before, during, and after SRS is a major factor in how well and how quickly the individual recovers, and his or her satisfaction with this part of the transition experience. For both MTF and FTM persons, pre-procedure communication with surgeons and other members of the health care team is essential to a healthy recovery -- and to avoiding acquiring or transmitting HIV following surgery. Individuals should make sure they understand how long the healing time is for genital surgeries; sexual activity too soon may allow HIV to enter the body through unhealed surgical wounds or may put partners at risk for HIV transmitted through blood from surgical sites.
Once healing is complete, safersex tools like male or female condoms, dental dams, and latex gloves cut to fit a new "microphallus" can help protect the transgender individual and his or her sex partners from HIV and other sexually transmitted infections. Transgender women with neovaginas should be aware that most reconstructed vaginas cannot lubricate naturally; using a personal lubricant is recommended to decrease the likelihood that sex will cause abrasions and small tears through which HIV and other pathogens can pass. Care for a neovagina includes periodic dilation to prevent stenosis (narrowing). Microscopic tears caused by dilation or sex create ideal conditions for acquiring or transmitting HIV if barrier protection is not used during sexual intercourse.
In addition, the medical care team should be aware of any and all medications (including ART) the individual undergoing surgery is using to ensure continuity and avoid drug interactions during and after surgery. And regardless of their HIV status, transgender individuals who have had any sex reassignment surgery but retain pretransition organs or tissue remnants need regular screening for cancers commonly associated with their birth sex, including prostate, breast, cervical, and ovarian cancers.
"I try to model that I am comfortable talking, that [transgenderism] is nothing exotic. Routinize it, make it ordinary -- but at the same time acknowledge that, for many transgender patients, their past has been very challenging and overwhelming."
Because transgender health needs are complex and may intimidate health care providers, and due to the general lack of culturally competent medical settings, transgender people may struggle to find appropriate medical care. Lack of stable employment and other financial barriers may also hinder access to health insurance and medical care. Other barriers to care include fear of exposure or disclosure, geographic isolation, social isolation, and a dearth of transgender-specific clinical research and medical literature. Lack of gender-variance variables on medical history forms may also present an obstacle to care.
In addition, health insurance policies may not cover expensive treatments and surgeries sought by many transgender people; most insurance companies, employee health plans, and health maintenance organizations (HMOs) specifically exempt coverage for sex reassignment surgery, hormones, and electrolysis, deeming them elective or cosmetic.
Thus, both real and perceived discrimination in medical settings, in addition to most providers' lack of experience working with transgender clients, may keep transgender individuals from accessing appropriate medical treatment, seeking legal hormones, or getting tested and/or treated for HIV. In a fourcity study of antiretroviral drug use, for example, transgender persons had significantly lower rates of ART use compared with other populations.
Important guidelines developed by the Center of Excellence for Transgender HIV Prevention encourage medical providers to ask themselves whether the questions they are posing to transgender clients are medically necessary and relevant to their work. The California STD/HIV Prevention Training Center teaches providers working with transgender clients to frame questions in terms of what the provider needs to know and what he or she already knows, and how to ask questions sensitively. Structuring communication with patients in this way will hopefully prevent providers and medical office staff from "asking unnecessary or inappropriate questions that lead to making assumptions or lead to making the client or patient feel uncomfortable," says Jen Shockey, MPH, Behavioral Intervention Trainer at the California STD/HIV Prevention Training Center.
At the same time, it is essential that patient-provider communication be open and frank in order to ensure the best possible care. Says Lisa Capaldini, MD, "Don't make any assumptions. Ask. Just like you can't make any assumptions on sexual behavior based on whether someone is gay or straight, we really don't know anything about what (if any) medical, hormonal, or surgical treatments a trans person has had short of taking a focused and detailed history." The key is to make this historytaking as comfortable as possible for the patient, and, as JoAnne Keatley, MSW, puts it, this requires "grounding your work in the community." Best practices for health care rely on provider education: "Being responsive to the needs of the patient -- educating yourself around who the transgender community is and how to engage with them and address their health care needs -- is the most important practice that providers can incorporate into their [medical] practice."
The following simple practices, recommended by WPATH and TWHC, can help medical providers offer a comfortable environment and sensitive treatment for transgender clients.
Use appropriate pronouns and language:
Acknowledge geographic and social isolation and potential trauma history:
The transgender population is severely underserved and carries a disproportionate burden of HIV nationally and internationally. Many transgender individuals are uniquely dependent on an often inadequate health care system because their gender identity depends on feminizing or masculinizing medical procedures. All transgender persons, whether seeking such procedures or not, should have access to adequate medical care -- including prevention of and treatment for HIV and other conditions -- in a sensitive and supportive setting.
By adopting the practices recommended by the Center of Excellence for Transgender HIV Prevention, the Tom Waddell Health Center, and other transgender-focused organizations, health-care providers can take significant steps toward relieving some of the health disparities experienced by transgender persons. And by accessing the resources highlighted in this article, transgender individuals can become their own advocates in health clinics and doctors' offices and work better with providers to optimize their own health and well-being.
Kimberly Keller, MSc, recently served as the San Francisco AIDS Foundation's Research Analyst and helped to develop a peer-education program on acute HIV infection for the San Francisco Bay Area male-to-female transgender population.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (Text Revision). Arlington, VA: American Psychiatric Publishing, Inc. 2000.
Bockting, W. Transgender identity and HIV: Resilience in the face of stigma. Focus: A Guide to AIDS Research and Counseling from the AIDS Health Project. 23(2):1-4. Spring 2008.
Bockting, W. and others. Transgender HIV prevention: A qualitative needs assessment. AIDS Care 10(4):505-25. August 1998.
Bowman, C. and J. Goldberg. Care of the patient undergoing sex reassignment surgery. International Journal of Transgenderism 9(3/4):135-165. 2006.
Clements-Nolle, K. and others. HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: Implications for public health intervention. American Journal of Public Health 91(6):915-21. June 2001.
De Cuypere, G. and others. Prevalence and demography of transsexualism in Belgium. European Psychiatry 22(3):137-41. April 2007.
Edney, R. To keep me safe from harm? Transgender prisoners and the experience of imprisonment. Deakin Law Review 9(2):327-38. 2004.
Feldman, J. and J. Goldberg. Transgender primary medical care. International Journal of Transgenderism 9(3/4):3-34. June 2007.
Herbst, J. and others. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: A systematic review. AIDS and Behavior 12:1-17. January 2008.
Keatley, J. and others. Transgender global HIV/AIDS epidemiology. Presentation at the 17th International AIDS Conference. Mexico City. August 3-8, 2008.
Kessler, S. and W. McKenna. Who put the "trans" in transgender? Gender theory and everyday life. International Journal of Transgenderism 4(3). July-September 2000.
Mayer K. and others. Sexual and gender minority health: What we know and what needs to be done. American Journal of Public Health 98(6):989-94. June 2008.
Nemoto, T. and others. Health and social services for male-to-female transgender persons of color in San Francisco. International Journal of Transgenderism 8(2/3):5-19. 2005.
Nemoto, T. and others. HIV risk behaviors among male-tofemale transgender persons of color in San Francisco. American Journal of Public Health 94 (7):1193-99. July 2004.
Operario, D. Outside the box: HIV prevention with hardto- categorize people. Focus: A Guide to AIDS Research and Counseling from the AIDS Health Project 23(2):5-8. Spring 2008.
Tom Waddell Health Center. Protocols for hormonal reassignment of gender. December 2006. http://www.sfdph.org/dph/comupg/oservices/medSvs/hlthCtrs/TransGendprotocols122006.pdf.
van Kesteren, P. and others. Mortality and morbidity in transsexual patients treated with cross-sex hormones. Clinical Endocrinology 47(3):337-42. September 1997.
Want to read more articles in the Summer/Fall 2009 issue of Bulletin of Experimental Treatments for AIDS? Click here.
This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)